Adult Brain Malignant Hemangiopericytoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Malignant Meningioma, Adult Rhabdomyosarcoma, Chondrosarcoma
Conditions
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.
Detailed description
OBJECTIVES: * Estimate failure free survival, overall survival, and response in patients with residual or recurrent/progressive aggressive meningeal tumors (malignant meningioma, hemangiopericytoma, and primary nervous system sarcoma) treated with ifosfamide. * Evaluate toxicities of ifosfamide in this patient population. OUTLINE: All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course. Patients are evaluated for response/progression after every 2 courses. Patients with stable disease receive up to 8 courses of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months thereafter. PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study.
Interventions
DRUGifosfamide
Sponsors
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
SWOG Cancer Research Network
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically proven recurrent or unresectable: * Malignant meningioma * Intracranial hemangiopericytoma * Primary central nervous system sarcoma, including: * Fibrosarcoma * Rhabdomyosarcoma * Chondrosarcoma * Leiomyosarcoma * Measurable or evaluable disease on CT or MRI scan * Persistent disease following biopsy or incomplete resection OR * Recurrent disease following complete resection * No benign meningioma * No prior or current systemic sarcoma PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * SWOG 0-2 Life expectancy: * Not specified Hematopoietic: * WBC at least 3,000/mm\^3 * Absolute granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Not specified Renal: * Creatinine no greater than 2.0 mg/dL Cardiovascular: * No myocardial infarction within the past 3 months * No active angina * No unstable heart rhythms * No congestive heart failure Other: * HIV negative * No allergy to study drugs * No serious concurrent medical or psychiatric illness * No uncontrolled peptic ulcer disease * No prior malignancy within past 5 years except adequately treated: * Basal or squamous cell carcinoma of the skin * Carcinoma in situ of the cervix * Not pregnant or nursing * Effective contraception required of fertile patients PRIOR CONCURRENT THERAPY: * Recovered from toxic effects of prior therapy and/or from postoperative complications Biologic therapy: * Not specified Chemotherapy: * No prior ifosfamide * No other concurrent chemotherapy Endocrine therapy: * No concurrent hormonal therapy (except estrogen replacement therapy) * Corticosteroids allowed if dose is stable or decreasing Radiotherapy: * At least 4 weeks since prior radiotherapy * Progressive disease following radiation required * No concurrent radiotherapy Surgery: * See Disease Characteristics
Countries
Australia, Peru, Puerto Rico, United States
Outcome results
None listed